Cellectis, Stemgent Partner on Genome Engineering, mRNA Reprogramming | GenomeWeb

NEW YORK (GenomeWeb News) – Cellectis bioresearch, a subsidiary of Cellectis group, today said that it has partnered with Stemgent to provide research services that combine mRNA reprogramming and genome engineering.

The firms said that the combination of their technologies would "pave the way for clinically-relevant applications in regenerative medicine." Terms of the alliance were not disclosed.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

The price of plane tickets can affect how scientists in different countries choose to collaborate with each other, NPR reports.

The Annals of Improbable Research has awarded the 2016 Ig Nobel Prizes.

Scientific American alleges that the FDA has been "arm-twisting journalists into relinquishing their reportorial independence."

In Science this week: a global genetic interaction map for Saccharomyces cerevisiae, and progress made in genomics, precision medicine, and therapeutics.